PAI Holdings, LLC, dba Pharmaceutical Associates, Inc – FDA 483, Sep 2, 2022
VistaPharm, Inc. in Largo, FL, a drug manufacturer, was inspected and cited for significant deficiencies across three observations. The inspection revealed inadequate production and process controls for Clobazam Oral Suspension, unsanitary conditions due to vermin infestation in manufacturing areas, and failures within the quality control unit regarding Annual Product Reviews, finished product labeling, and good documentation practices. These issues indicate a lack of adherence to cGMP regulations.
- Inspection date
- September 2, 2022
- Product type
- drugs
ID · 6938858a-0ca4-44c0-a078-a4f6939e8a57
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.